Quantitative Flow Ratio to Predict Non-Target-Vessel Events Prior to Planned Staged PCI in ACS Patients
暂无分享,去创建一个
S. Bär | S. Losdat | Md Mph | R. Md | T. Md | Y. Md | Jonas Häner MD PhD | J. Md | Monika Fürholz MD MSc | F. Md | MD Lukas Hunziker | George CM Siontis Md | Thomas Pilgrim PhD | Stefan Stortecky MD MSc | Stephan Windecker PhD | L. Md | Prof. Lorenz Räber
[1] J. Escaned,et al. Improved Nonculprit Stenosis Assessment in Patients With ST-Segment Elevation Myocardial Infarction Using Quantitative Flow Ratio. , 2023, JACC. Cardiovascular interventions.
[2] E. Boersma,et al. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial , 2023, The Lancet.
[3] Yan Lai,et al. Angiographic quantitative flow ratio in acute coronary syndrome: beyond a tool to define ischemia-causing stenosis—a literature review , 2022, Cardiovascular diagnosis and therapy.
[4] L. Räber,et al. Effect of Timing of Staged Percutaneous Coronary Intervention on Clinical Outcomes in Patients With Acute Coronary Syndromes , 2021, Journal of the American Heart Association.
[5] P. Serruys,et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial , 2021, The Lancet.
[6] S. Bangalore,et al. Prognostic value of fractional flow reserve using computed tomography for predicting major adverse cardiac events and mortality in kidney transplant candidates , 2021, European Heart Journal.
[7] G. Chatellier,et al. Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. , 2021, The New England journal of medicine.
[8] L. Räber,et al. Quantitative Flow Ratio to Predict Nontarget Vessel–Related Events at 5 Years in Patients With ST‐Segment–Elevation Myocardial Infarction Undergoing Angiography‐Guided Revascularization , 2021, Journal of the American Heart Association.
[9] Deepak L. Bhatt,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.
[10] F. Neumann,et al. The Natural History of Nonculprit Lesions in STEMI: An FFR Substudy of the Compare-Acute Trial. , 2020, JACC. Cardiovascular interventions.
[11] C. Macaya,et al. Angiography-derived functional assessment of non-culprit coronary stenoses during primary percutaneous coronary intervention for ST-elevation myocardial infarction. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[12] Marco Valgimigli,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.
[13] M. Keltai,et al. Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial. , 2019, Journal of the American College of Cardiology.
[14] Á. Avezum,et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. , 2019, The New England journal of medicine.
[15] Ajay K. Jain,et al. Complete Versus Culprit-Only Lesion Intervention in Patients With Acute Coronary Syndromes. , 2018, Journal of the American College of Cardiology.
[16] Jeroen J. Bax,et al. Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis , 2018, European heart journal.
[17] H. Bøtker,et al. Diagnostic Performance of In‐Procedure Angiography‐Derived Quantitative Flow Reserve Compared to Pressure‐Derived Fractional Flow Reserve: The FAVOR II Europe‐Japan Study , 2018, Journal of the American Heart Association.
[18] A. M. Leone,et al. Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment–Elevation Myocardial Infarction and Multivessel Disease , 2018, Circulation. Cardiovascular interventions.
[19] F. Fedele,et al. Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial. , 2016, Journal of the American College of Cardiology.
[20] L. Køber,et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial , 2015, The Lancet.
[21] T. Jernberg,et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.
[22] H. Swanton,et al. Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease , 2015, Journal of the American College of Cardiology.
[23] C. Berry,et al. Randomized trial of preventive angioplasty in myocardial infarction. , 2013, The New England journal of medicine.
[24] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[25] N. Pijls,et al. The crux of maximum hyperemia: the last remaining barrier for routine use of fractional flow reserve. , 2011, JACC. Cardiovascular interventions.
[26] Akiko Maehara,et al. A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.
[27] U. Siebert,et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. , 2010, Journal of the American College of Cardiology.
[28] P. Serruys,et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[29] F. Loop,et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Circulation.
[30] G. Thanassoulis,et al. Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction. , 2017, The New England journal of medicine.
[31] J. Mehilli,et al. [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. , 2016, Giornale italiano di cardiologia.
[32] K. Mahaffey,et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .